Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7597972 | 0.85 | TSHR (0.45) | TSHRRAB9ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL2288616 | 0.85 | SMN1; SMN2 (0.46) | TSHRRAB9ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL6427847 | 0.84 | TSHR (0.49) | TSHRRAB9ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL5805479 | 0.83 | TSHR (0.57) | TSHRRAB9ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL8516064 | 0.81 | ALDH1A1 (0.59) | TSHRSMN1; SMN2ALDH1A1MAPTKDM4E | |
| SCHEMBL4207496 | 0.81 | TSHR (0.51) | TSHRRAB9ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL7498798 | 0.80 | TSHR (0.48) | TSHRRAB9ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL10694643 | 0.79 | TSHR (0.49) | TSHRRAB9ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL5461474 | 0.78 | NPC1 (0.61) | RAB9ASMN1; SMN2ALDH1A1NPC1MEN1 | |
| SCHEMBL10695523 | 0.78 | TSHR (0.49) | TSHRRAB9ASMN1; SMN2ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2590949-B1 | METHOD FOR MANUFACTURING OF QUINOLINE-3-CARBOXAMIDES | ACTIVE BIOTECH AB (SE) | 2015-11-25 | — | — | EP | disclosed |
| CN-103119023-B | Improved method for manufacturing of quinoline-3-carboxamides | ACTIVE BIOTECH AB | 2014-12-24 | — | — | CN | disclosed |
| US-8871936-B2 | Method for manufacturing of quinoline-3-carboxamides | ACTIVE BIOTECH AB (SE) | 2014-10-28 | — | — | US | disclosed |
| CN-103119023-A | Method for manufacturing of quinoline-3-carboxamides | ACTIVE BIOTECH AB | 2013-05-22 | — | — | CN | disclosed |
| EP-2590949-A1 | METHOD FOR MANUFACTURING OF QUINOLINE-3-CARBOXAMIDES | Active Biotech AB (SE) | 2013-05-15 | — | — | EP | disclosed |
| US-20130109860-A1 | METHOD FOR MANUFACTURING OF QUINOLINE-3-CARBOXAMIDES | ACTIVE BIOTECH AB (SE) | 2013-05-02 | — | — | US | disclosed |
| WO-2012004338-A1 | METHOD FOR MANUFACTURING OF QUINOLINE-3-CARBOXAMIDES | ACTIVE BIOTECH AB (SE) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109860-A1 | METHOD FOR MANUFACTURING OF QUINOLINE-3-CARBOXAMIDES | ADH1A, ADH5, ADH1C | TSHR 2053/4885RAB9A 569/4885SMN1; SMN2 2209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.